Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
Type
Subsidiary
HQ
Welwyn Garden City, GB
Founded
2007
Heptares Therapeutics was founded in 2007 and is headquartered in Welwyn Garden City, GB
Report incorrect company information

Heptares Therapeutics Office Locations

Heptares Therapeutics has an office in Welwyn Garden City
Welwyn Garden City, GB (HQ)
Broadwater Rd
Show all (1)
Report incorrect company information

Heptares Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2007

Total Funding

$26 m

Investors

In total, Heptares Therapeutics had raised $26 m

Heptares Therapeutics Financials

Heptares Therapeutics's revenue was reported to be £102.25 m in FY, 2017
GBPFY, 2012FY, 2013FY, 2014FY, 2016FY, 2017

Revenue

5.6 m9.7 m5.2 m17 m102.2 m

Operating expense total

12.7 m15.5 m16.1 m35 m23.3 m

EBITDA

(5.2 m)(10.4 m)(17.4 m)79.4 m

EBITDA margin, %

(53%)(201%)(102%)78%
GBPFY, 2012FY, 2013FY, 2014FY, 2016FY, 2017

Net Income

(5.3 m)(4.2 m)(8.2 m)(8.7 m)67.9 m

Cash From Operating Activities

(7.1 m)(4.7 m)(11.8 m)

Cash From Financing Activities

8.5 m6.5 m9 m

Net Change in Cash

2.5 m3.2 m(1.4 m)
Show all financial metrics
Report incorrect company information